Novavax CEO Stanley Erck at the White House in 2020 (Andrew Harnik, AP Images)
April 21, 2021 11:45 AM EDTUpdated 04:15 PM
Coronavirus
In Focus

As fears mount over J&J and As­traZeneca, No­vavax en­ters a shaky spot­light

Jason Mast

Editor

As con­cerns rise around the J&J and As­traZeneca vac­cines, glob­al at­ten­tion is in­creas­ing­ly turn­ing to the lit­tle, 33-year-old, pro­duct­less, bank­rupt­cy-flirt­ing biotech that could: No­vavax. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times